http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1934872-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8ed6f350e02f2da234ca8ed25bee0ad |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-9486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-94 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 |
| filingDate | 2006-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0af42006a66b537437824b8cb9e1a0f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4a86cb1e5e2569da6922277dc36087e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be8737050e9dba45eb62d6e4f2130111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_876dc2458bfaacc81fcb5247c1e2c816 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_065af7738afdc8c467d2105958ce9acb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e439254bded30d7bf8975376117f7fc |
| publicationDate | 2008-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1934872-A2 |
| titleOfInvention | Development of prodrugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety using in vitro/in silico predictions |
| abstract | The present invention provides a method of using a physiologically-based pharmacokinetic model to select a prodrug molecule (NO-X) comprising a therapeutic agent X (e.g. nonsteroidal anti-inflammatory drug, (NSAID)) and an appropriate nitric oxide donor NO. The NSAID can be a non-selective or selective cyclooxygenase inhibitor or other biocompatible compound comprising a carboxyl group. The pharmacokinetic model uses in vitro and/or in silico data to estimate an optimal set of parameters that can predict whether a particular NO-X candidate is capable of producing desirable therapeutic effects, e.g. enhanced antiiflammatory activity, reduced intestinal, cardiac and renal toxicity. Accordingly, the present invention may help with proper selection of an appropriate candidate for drug development, with less development time and at lower cost. |
| priorityDate | 2005-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 832.